URINARY SYMPTOMS IN PATIENTS WITH MULTIPLE SCLEROSIS. AS UROLOGISTS, ARE WE IMPORTANT IN THE ALGORITHM OF SPECIALIZED CARE OF PATIENT WITH MULTIPLE SCLEROSIS?

Česká verzia

Authors: Zuzana Vaľová; Libor Zámečník; Roman Sobotka; Yvona Pichlíková; Květoslav Novák; Tomáš Hanuš
Authors place of work: Urologická klinika VFN a 1. LF UK, Praha
Published in the journal: Ces Urol 2016; 20(4): 259-274
Category: Review article

Summary

Major statement:
This article summarizes the basic information about urological complications of multiple sclerosis diagnosis and treatment of urological symptoms of this disease.

Multiple sclerosis (MS) is a serious autoimmune disease of the central nervous system (CNS) of young patients. Untreated patients experience marked disability and serious deterioration of their socio-economic status and quality of life. Physiological CNS environment is disturbed by two processes – the formation of focal demyelinating plaques and diffuse CNS involvement.

From the urological point of view, an important fact is that almost in all patients with MS the structures involved in the innervation of the lower urinary tract are eventually involved, which is reflected by voiding problems being among the common symptoms of MS.

The aim of this work is to summarize the information about multiple sclerosis from the urological perspective and consider the resulting algorithm of specialized care especially with regard to noninvasive and mini-invasive possibilities.

Key words:
Voiding dysfunction, postvoiding residual urine, multiple sclerosis, urodynamics.

Zdroje

1. Vachová M. Epidemie roztroušené sklerózy ve světě? Cesk Slov Neurol N 2012; 75/106(6): 701–706.

2. Dufek M. Roztroušená skleróza – EDSS (expanded disability status scale), tzv. Kurtzkeho škála. Neurol. praxi 2011; 12(Suppl. G): 6–9.

3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444–1452.

4. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria“. Annals of neurology 2005; 58(6): 840–846.

5. Zapletalová O. Léčba časných stadií roztroušené sklerózy mozkomíšní. Remedia 2009; 19(3): 198–204.

6. Araki I, Matsui M, Ozawa K, Takeda M, Kuno S. Relationship of bladder dysfunction to lesion site in multiple sclerosis. The Journal of urology 2003; 169(4): 1384–1387.

7. Zámečník L, Novák K, Soukup V, et al. Závisí vývoj dysfunkce mikce u roztroušené sklerózy na typu neurologické léčby? Cesk Slov Neurol N 2007; 70(6): 687–691.

8. Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. European urology 2016; 69(2): 324–333.

9. Wheeler JS, Jr, Siroky MB, Pavlakis AJ, Goldstein I, Krane RJ. The changing neurourologic pattern of multiple sclerosis. The Journal of urology 1983; 130(6): 1123–1126.

10. de Seze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple sclerosis (Houndmills, Basingstoke, England) 2007; 13(7): 915–928.

11. Amarenco G, de Seze M, Ruffion A, Sheikh Ismael S. Clinical and urodynamic evaluations of urinary disorders in multiple sclerosis. Annals of physical and rehabilitation medicine 2014; 57(5): 277–287.

12. Manack A, Motsko SP, Haag-Molkenteller C, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourology and urodynamics 2011; 30(3): 395–401.

13. Groen J, Pannek J, Castro Diaz D. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. Eur Urol. 2016; 69(2): 324–333.

14. Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia 1990; 28(4): 217–229.

15. Zámečník L, Novák K, Hanuš T. Pacient s roztroušenou sklerózou v ordinaci praktického urologa. Urol. praxi 2001; 2(1): 58–62.

16. Fletcher SG, Dillon BE, Gilchrist AS, et al. Renal deterioration in multiple sclerosis patients with neurovesical dysfunction. Multiple sclerosis (Houndmills, Basingstoke, England) 2013; 19(9): 1169–1174.

17. Krhut J, Hradilek P, Zapletalova O. Analysis of the upper urinary tract function in multiple sclerosis patients. Acta neurologica Scandinavica 2008; 118(2): 115–119.

18. Krhut J, Hradílek P, Mainer K, Zapletalová O. Nové schéma v diagnostice a terapii dysfunkcí dolních močových cest u pacientů s roztroušenou sklerózou. Urol. praxi 2005; 6(5): 209–212.

19. Del Popolo G, Panariello G, Del Corso F, De Scisciolo G, Lombardi G. Diagnosis and therapy for neurogenic bladder dysfunctions in multiple sclerosis patients. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2008; 29 Suppl 4: S352–355.

20. Colli E, Artibani W, Goka J, Parazzini F, Wein AJ. Are urodynamic tests useful tools for the initial conservative management of non-neurogenic urinary incontinence? A review of the literature. European urology 2003; 43(1): 63–69.

21. Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. The Lancet Neurology 2015; 14(7): 720–732.

22. Dillon BE, Lemack GE. Urodynamics in the evaluation of the patient with multiple sclerosis: when are they helpful and how do we use them? The Urologic clinics of North America 2014; 41(3): 439–444, ix.

23. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgraduate medical journal 2009; 85(1008): 552–559.

24. Zámečník L. Mikční a sexuální poruchy. In: Havrdová E, editor. Roztroušená skleróza. Praha: Mladá Fronta; 2013. 125–131.

25. Urodynamics. In: Urinary Incontinence in Neurological Disease, Management of Lower Urinary Tract Dysfunction in Neurological Disease. NICE Clinical Guidelines, No. 148. London: Royal College of Physicians (UK); 2012. 53–63.

26. Lucio AC, Campos RM, Perissinotto MC, et al. Pelvic floor muscle training in the treatment of lower urinary tract dysfunction in women with multiple sclerosis. Neurourology and urodynamics 2010; 29(8): 1410–1413.

27. De Ridder D, Vermeulen C, Ketelaer P, Van Poppel H, Baert L. Pelvic floor rehabilitation in multiple sclerosis. Acta neurologica Belgica 1999; 99(1): 61–64.

28. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Advances in urology 2011; 2011: 834753.

29. Zámečník L. Symptomatická terapie roztroušené sklerózy – mikční potíže. In: Havrdová E, editor. Roztroušená skleróza. Praha: Mladá Fronta; 2013. 378–382.

30. Otsuki H, Kosaka T, Nakamura K, et al. Beta3-adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. International urology and nephrology 2013; 45(1): 53–60.

31. Freeman RM, Adekanmi O, Waterfield MR, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). International urogynecology journal and pelvic floor dysfunction 2006; 17(6): 636–641.

32. Preiningerová Lízrová J, Štětkářová I. Symptomatická terapie roztroušené sklerózy. Léčba spasticity a porucha chůze. In: Havrdová E, editor. Roztroušená skleróza. Praha: Mladá Fronta; 2013. 370–378.

33. Mahadeva A, Tanasescu R, Gran B. Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large University Hospital. American journal of clinical and experimental immunology 2014; 3(1): 57–67.

34. Moore KN, Murray S, Malone-Lee J, Wagg A. Rapid urinalysis assays for the diagnosis of urinary tract infection. British journal of nursing (Mark Allen Publishing) 2001; 10(15): 995–1001.

35. Rakusa M, Murphy O, McIntyre L, et al. Testing for urinary tract colonization before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation. European journal of neurology: the official journal of the European Federation of Neurological Societies 2013; 20(3): 448–452.

36. Hanuš T. Intermitentní katetrizace močového měchýře. Čas Lék Čes 1983; 122: 1135–1137.

37. Krhut J. Intermitentní katetrizace. In: Krhut J, editor. Neurourologie. Praha Galén; 2005. 37–40.

38. Šámal V, Kyriánová A, Šrám J, Mečl J, Fogl J. Čistá intermitentní autokatetrizace u neurogenních dysfunkcí dolních močových cest po spinálním poranění. Porovnávání výsledků při použití hydrofilnch a standardních PVC katetrů. Ces Urol 2011; 15(4): 229–236.

39. Nicholas R, Young C, Friede T. Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. Expert opinion on drug safety 2010; 9(6): 905–915.

40. Krhut J. Neinvazivní neuromodulace a neurostimulace. In: Krhut J, editor. Neurourologie. Praha Galén; 2005. 46–47.

41. Rejchrt M. Využití neuromodulace v léčbě dysfunkcí dolních cest močových. Ces Urol 2012; 16(1): 5–12.

42. McClurg D, Ashe RG, Lowe-Strong AS. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis-a double blind, placebo controlled, randomised clinical trial. Neurourology and urodynamics 2008; 27(3): 231–237.

43. Schurch B, Carda S. Onabotulinumtoxin A and multiple sclerosis. Annals of physical and rehabilitation medicine 2014; 57(5): 302–314.

44. Krhut J. Aplikace botulotoxinu do detruzoru. In: Krhut J, editor. Neurourologie. Praha Galén; 2005: 44–46.

45. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. The Journal of urology 2005; 174(1): 196–200.

46. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. The Journal of urology 2012; 187(6): 2131–2139.

47. Sirls LT, Zimmern PE, Leach GE. Role of limited evaluation and aggressive medical management in multiple sclerosis: a review of 113 patients. The Journal of urology 1994; 151(4): 946–950.

48. Gough DC. Enterocystoplasty. BJU international 2001; 88(7): 739–743.

49. DeLong J, Tighiouart H, Stoff el J. Urinary diversion/reconstruction for cases of catheter intolerant secondary progressive multiple sclerosis with refractory urinary symptoms The Journal of urology 2011; 185(6): 2201–2206

50. Castro-Diaz D, Barret D, Grise P. Surgery for the neuropathic patient In: Abrams P, Khoury S, Wein A, editors Incontinence Plymouth: Health Publication; 2002

51. Krhut J. Dysfunkce typu A (hyperaktivní detruzor + hyperaktivní sfinkter) – operační metody léčby In: Krhut J, editor Neurourologie Praha Galén; 2005 49–66

52. Ženíšek J. Novinky v léčbě stresové inkontinence u mužů Urol praxi 2014; 12(2): 68–71

53. Pan D, Troy A, Rogerson J, et al. Long‑term outcomes of external sphincterotomy in a spinal injured population The Journal of urology 2009; 181(2): 705–709

54. Seoane-Rodriguez S, Sanchez RLJ, Montoto-Marques A, et al. Long‑term follow‑up study of intraurethral stents in spinal cord injured patients with detrusor‑sphincter dyssynergia Spinal cord 2007; 45(9): 621–626

55. Schwartz SL, Kennelly MJ, McGuire EJ, Faerber GJ. Incontinent ileo‑vesicostomy urinary diversion in the treatment of lower urinary tract dysfunction The Journal of urology 1994; 152(1): 99–102

56. Minardi D, Muzzonigro G. Sacral Neuromodulation in patients with multiple sclerosis Worl J Urol 2012; 30(1): 123–128.